PecFent Nasal Spray

Name PecFent nasal spray

Each ml of solution contains 1,000 micrograms fentanyl (as citrate)

1 spray (100 microlitres) contains 100 micrograms fentanyl (as citrate)

Each bottle contains 1.55 ml (1,550 micrograms fentanyl).

Indication PecFent is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.

PectFent is available in two strengths: 100 micrograms/spray and 400 micrograms/spray
Initial dose

  • The initial dose of PecFent to treat episodes of BTP is always 100 micrograms (one spray), even in patients switching from other fentanyl containing products for their BTP.
  • Patients must wait at least 4 hours before treating another episode of BTP with PecFent.

Method of titration

  • Patients should be prescribed an initial titration supply of one bottle (8 sprays) of PecFent 100 micrograms/spray.
  • Patients whose initial dose is 100 micrograms and who need to titrate to a higher dose due to a lack of effect can be instructed to use two 100 microgram sprays (one in each nostril) for their next BTP episode. If this dose is not successful, the patient may be prescribed a bottle of PecFent 400 micrograms/spray and instructed to change to one 400 microgram spray for their next episode of pain. If this dose is not successful, the patient may be instructed to increase to two 400 microgram sprays (one in each nostril).
  • From treatment initiation, patients should be closely followed and the dose titrated until an effective dose is reached and confirmed for two consecutively treated episodes of BTP.
 Regulatory Status

EMA approved in June 2010; FDA approved in June 2011

Under registration in the MEA region

 Business Partner Kyowa Hakko Kirin Co. Ltd